A Survey of Drug Burden in Patients Undergoing Maintenance Hemodialysis in Japan

Objective This report presents a part of a survey pertaining to drug burden in maintenance hemodialysis patients in Japan. Methods A patient-reported questionnaire-based survey was conducted from September to November 2016 in six regions in Japan. Patients A total of 700 patients (50-79 years old) on maintenance hemodialysis for >3 years and members of the Japan Association of Kidney Disease Patients (JAKDP) were provided with the questionnaire. They were randomly selected using stratified sampling according to patient distribution observed from the Japanese Society for Dialysis Therapy Renal Data Registry (JSDT JRDR). Results A total of 524 (74.9%) patient questionnaires were evaluated [mean (standard deviation; SD) age, 66.6 (7.2) years; males, 63.4%; dialysis vintage, 16.9 (9.1) years]. Patients' age, gender, and regional distribution were similar to the JSDT JRDR. They were taking an average (SD) of 16.4 (8.34) and 16.3 (8.55) oral medications/day on dialysis and nondialysis days, respectively. A majority of the patients were taking ≥10 oral medications/day on dialysis (75.1%) and nondialysis (74.4%) days, with phosphate binders being the most taken (7.0 tablets/day). A similar proportion (74.4%, 72.9%, respectively) was taking ≥6 different types of oral medications/day. Most patients were taking oral medications 3 (31%, 33%), 4 (24%, 22%), and ≥5 times (31%, 30%) a day, respectively. The drug burden was similar on dialysis and nondialysis days and did not vary with dialysis vintage. Conclusion The number, type, and frequency of oral medications in maintenance hemodialysis patients are high in Japan. The proportion of phosphate binders was highest among the prescription medications.

[1]  S. Ito,et al.  Diabetes mellitus as a cause or comorbidity of chronic kidney disease and its outcomes: the Gonryo study , 2018, Clinical and Experimental Nephrology.

[2]  K. Wakai,et al.  Annual Dialysis Data Report 2014, JSDT Renal Data Registry (JRDR) , 2017, Renal Replacement Therapy.

[3]  J. Ballarín,et al.  Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism , 2015 .

[4]  K. Wakai,et al.  An Overview of Regular Dialysis Treatment in Japan (As of 31 December 2013) , 2015, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[5]  Chul-woo Yang,et al.  Impact of Dialysate Calcium Concentration on Clinical Outcomes in Incident Hemodialysis Patients , 2015, Medicine.

[6]  C. Wanner.  Moderator's view: treatment of vascular calcification is a physical impossibility, so far. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  S. Nakai,et al.  An overview of regular dialysis treatment in Japan (As of December 31, 2012) , 2014 .

[8]  M. Fukagawa,et al.  A Japanese approach for CKD-MBD , 2013, Kidney international supplements.

[9]  M. Dorgan,et al.  Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis , 2013, The Lancet.

[10]  K. Iseki,et al.  Clinical Practice Guideline for the Management of Chronic Kidney Disease‐Mineral and Bone Disorder , 2013, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[11]  M. Cozzolino.  Prevention and Treatment of CKD-MBD , 2013, Nephro-urology monthly.

[12]  M. Soma,et al.  Mineral Metabolic Abnormalities and Mortality in Dialysis Patients , 2013, Nutrients.

[13]  K. Iseki.  Nephrology for the people: Presidential Address at the 42nd Regional Meeting of the Japanese Society of Nephrology in Okinawa 2012 , 2013, Clinical and Experimental Nephrology.

[14]  K. Mahaffey,et al.  Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. , 2012, The New England journal of medicine.

[15]  L. Gesualdo,et al.  VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH ≤ 150 pg/mL: results of the Italian FARO Survey. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  J. Fine,et al.  Characterizing daily life experience of patients on maintenance dialysis. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  F. Dekker,et al.  Progression of aortic calcification is associated with disorders of mineral metabolism and mortality in chronic dialysis patients. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  P. Raggi,et al.  The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  B. Hartmann,et al.  Adherence to prescribed oral medication in adult patients undergoing chronic hemodialysis: A critical review of the literature , 2009, European journal of medical research.

[20]  Yi-Wen Chiu,et al.  Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[21]  T. Shigematsu,et al.  Clinical significance of the K/DOQI bone guidelines in Japan. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[22]  G. Chertow,et al.  Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. , 2004, Journal of the American Society of Nephrology : JASN.

[23]  H. Manley,et al.  Medication prescribing patterns in ambulatory haemodialysis patients: comparisons of USRDS to a large not-for-profit dialysis provider. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[24]  K. Iseki,et al.  Analysis of drug prescription in chronic haemodialysis patients. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.